Cargando…
Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
OBJECTIVE: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization. MATERIALS AND METHODS: Eleven young women with stage Ia EC (International Federation of Gynecology an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671800/ https://www.ncbi.nlm.nih.gov/pubmed/28885274 http://dx.doi.org/10.1097/IGC.0000000000001109 |
_version_ | 1783276310155493376 |
---|---|
author | Wang, Fangfang Yu, Aijun Xu, Haichao Zhang, Xiaojing Li, Li Lou, Hanmei Yu, Hua Lin, Jun |
author_facet | Wang, Fangfang Yu, Aijun Xu, Haichao Zhang, Xiaojing Li, Li Lou, Hanmei Yu, Hua Lin, Jun |
author_sort | Wang, Fangfang |
collection | PubMed |
description | OBJECTIVE: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization. MATERIALS AND METHODS: Eleven young women with stage Ia EC (International Federation of Gynecology and Obstetrics grade 1) who were treated with a hysteroscopic approach combined with progestin from July 2004 to June 2016 were retrospectively analyzed and followed up to monitor their general recovery and pregnancy outcome. RESULTS: The patients' median age was 27.3 years (range, 25–39 years). Comorbidities consisted of primary infertility in 8 patients, polycystic ovary syndrome in 4, uterine fibroids in 2, and diabetes in 1. The results of immunohistochemical analysis were positive for all estrogen and progestin receptors. After treatment, 9 patients attained complete remission, and 2 patients achieved partial remission. The results of peritoneal cytology in 4 patients were negative. As of this writing, 6 of the 11 patients have given birth to 7 infants, and 1 patient had an ectopic pregnancy. Two patients ultimately underwent radical resection. The average follow-up time was 82.3 months (range, 15 to 152 months), and all patients remain disease-free. CONCLUSIONS: Hysteroscopic surgery combined with progestin treatment for stage Ia EC in young patients to avoid sterilization was practical and may represent a new option for patients with stage Ia EC who wish to preserve their fertility. |
format | Online Article Text |
id | pubmed-5671800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-56718002017-11-22 Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma Wang, Fangfang Yu, Aijun Xu, Haichao Zhang, Xiaojing Li, Li Lou, Hanmei Yu, Hua Lin, Jun Int J Gynecol Cancer Uterine Cancer OBJECTIVE: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization. MATERIALS AND METHODS: Eleven young women with stage Ia EC (International Federation of Gynecology and Obstetrics grade 1) who were treated with a hysteroscopic approach combined with progestin from July 2004 to June 2016 were retrospectively analyzed and followed up to monitor their general recovery and pregnancy outcome. RESULTS: The patients' median age was 27.3 years (range, 25–39 years). Comorbidities consisted of primary infertility in 8 patients, polycystic ovary syndrome in 4, uterine fibroids in 2, and diabetes in 1. The results of immunohistochemical analysis were positive for all estrogen and progestin receptors. After treatment, 9 patients attained complete remission, and 2 patients achieved partial remission. The results of peritoneal cytology in 4 patients were negative. As of this writing, 6 of the 11 patients have given birth to 7 infants, and 1 patient had an ectopic pregnancy. Two patients ultimately underwent radical resection. The average follow-up time was 82.3 months (range, 15 to 152 months), and all patients remain disease-free. CONCLUSIONS: Hysteroscopic surgery combined with progestin treatment for stage Ia EC in young patients to avoid sterilization was practical and may represent a new option for patients with stage Ia EC who wish to preserve their fertility. Lippincott Williams & Wilkins 2017-11 2017-08-31 /pmc/articles/PMC5671800/ /pubmed/28885274 http://dx.doi.org/10.1097/IGC.0000000000001109 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of IGCS and ESGO. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Uterine Cancer Wang, Fangfang Yu, Aijun Xu, Haichao Zhang, Xiaojing Li, Li Lou, Hanmei Yu, Hua Lin, Jun Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma |
title | Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma |
title_full | Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma |
title_fullStr | Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma |
title_full_unstemmed | Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma |
title_short | Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma |
title_sort | fertility preserved hysteroscopic approach for the treatment of stage ia endometrioid carcinoma |
topic | Uterine Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671800/ https://www.ncbi.nlm.nih.gov/pubmed/28885274 http://dx.doi.org/10.1097/IGC.0000000000001109 |
work_keys_str_mv | AT wangfangfang fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT yuaijun fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT xuhaichao fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT zhangxiaojing fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT lili fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT louhanmei fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT yuhua fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma AT linjun fertilitypreservedhysteroscopicapproachforthetreatmentofstageiaendometrioidcarcinoma |